论文部分内容阅读
目的:分析评估药物联合腹腔镜手术应用于子宫内膜异位症临床治疗中的效果及安全性。方法:参照完全随机对比原则,将2014年9月-2015年10月我院收治的子宫内膜异位症患者72例进行分组,得对照组(腹腔镜手术联合孕三烯酮治疗)和观察组(腹腔镜手术联合米非司酮)各36例,对比两组手术效果。结果:观察组的并发症发生率为8.33%,显著低于对照组(X2=6.79;P<0.05);观察组的VAS评分、子宫活动度以及CA125水平分别为(2.19±0.65)分、(0.45±0.07)、(27.57±4.19)U/m L,均显著低于对照组水平(t=11.94,12.48,13.75;P<0.05)。结论:利用米非司酮和孕三烯酮与腹腔镜手术联合应用于子宫内膜异位症的效果确切,但米非司酮更为安全,需对此引起充分重视。
Objective: To evaluate the efficacy and safety of drug combination laparoscopic surgery in the clinical treatment of endometriosis. Methods: With reference to the principle of complete randomization, 72 patients with endometriosis admitted from September 2014 to October 2015 in our hospital were divided into control group (laparoscopic surgery combined with gestrinone treatment) and observation Group (laparoscopic surgery combined with mifepristone) of 36 cases, compared the two groups of surgical results. Results: The incidence of complication in the observation group was 8.33%, which was significantly lower than that in the control group (χ2 = 6.79; P <0.05). The VAS score, uterine activity and the CA125 level in the observation group were (2.19 ± 0.65) 0.45 ± 0.07) and (27.57 ± 4.19) U / m L, respectively, which were significantly lower than the control group (t = 11.94,12.48,13.75; P <0.05). Conclusion: The combination of mifepristone and gestrinone in combination with laparoscopic surgery for endometriosis is effective, but mifepristone is more safe and needs more attention.